Treatment of cancer
AssigneeInnate Pharma
InventorManel Kraiem
Life of this patent
Estimating the term…
Abstract
The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents, for use in increasing sensitivity of tumors to the chemotherapeutic agents, for use in the treatment of cancers characterized by Nectin expressing tumor cells. In one embodiment, the present invention provides conjugates of an anti-Nectin-4 antibody to a camptothecin analogue, such as exatecan or SN-38, through a cleavable linker.
Claims9
A method of treating cancer in an individual comprising administering an anti-Nectin-4 antibody conjugated to a linker-exatecan moiety comprising Val-Ala-PAB-exatecan, wherein the exatecan molecule is coupled to PAB via the nitrogen atom of the amino group at position 1, such that the exatecan moiety when bound to the linker has the structure of Compound 1b:
- and
- wherein the cancer has relapsed and/or has progressed following treatment with a Nectin-4-binding agent conjugated to an auristatin.
Dependencies are inferred from the claim text.